Main menu

Nanopore Flongle sequencing as a rapid, single specimen clinical test for fusion detection


The identification of gene fusions is a cornerstone of diagnosis and treatment decision making for tumors of many forms and primary sites. Diverse molecular approaches are currently used for the molecular diagnosis of fusions, but few permit broad, partner agnostic detection of fusions over multiple potential targets. We previously described the combination of nanopore sequencing with the anchored multiplex PCR technique to permit a rapid testing paradigm.

Recently, a new platform for Nanopore sequencing has become publicly available, the Flongle flow cell from Oxford Nanopore Technologies (ONT), that offers lower throughput, but lower price testing. In this report, we describe the results of retesting of 15 specimens previously tested with both Illumina and ONT MinION sequencing. Further, we additionally blindly tested 13 specimens that had undergone clinical Illumina based sequencing.

We find that our Flongle sequencing pipeline removes key complexities of a multiplexed nanopore sequencing protocol, reduces sequencing turnaround time, and shows excellent concordance with Illumina results, and is particularly strong in identifying notoriously difficult to detect CIC-DUX4 translocations. We propose that features of the reported assay may make it of substantial interest for deployment in small to medium size molecular laboratories.

Authors: William R. Jeck, A. John Iafrate, Valentina Nardi

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag